Literature DB >> 34184975

CAR-based cell therapy: evaluation with bibliometrics and patent analysis.

Yajun Yuan1, Qihan Fu2, Yaqun Zhang3, Danhai Xu1, Yeqing Wu1, Qiufei Qiu1, Wuyuan Zhou1.   

Abstract

Chimeric antigen receptors-based cell therapies have shown impressive preclinical and clinical success and revolutionized biomedicine. However, the link between science and invention, the impact of international cooperation, and the influence and prestige of CARs research have not been explored. This study analyzed the landscape of peer-reviewed articles and patents related to CARs. A total of 5,681 publications were analyzed using bibliometrics and machine learning-based text mining to assess publication metrics, subject areas, and research hotspots. 5,010 Inpadoc families were also analyzed for patent filing trends, priority countries, and applicant and inventor rankings. The results show that CARs research has the following distinctive features: high research prestige among research community; strong global geographical bias in both academic output and patenting patterns; strong links between science and invention, but significant differences among countries; and an inverse relationship between country size and international collaboration rates.

Entities:  

Keywords:  CAR T cell therapy; Chimeric antigen receptors (CARs); bibliometrics; patent landscape; research hotspots

Mesh:

Year:  2021        PMID: 34184975      PMCID: PMC8827635          DOI: 10.1080/21645515.2021.1947100

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  46 in total

1.  NR4A transcription factors limit CAR T cell function in solid tumours.

Authors:  Joyce Chen; Isaac F López-Moyado; Hyungseok Seo; Chan-Wang J Lio; Laura J Hempleman; Takashi Sekiya; Akihiko Yoshimura; James P Scott-Browne; Anjana Rao
Journal:  Nature       Date:  2019-02-27       Impact factor: 49.962

2.  The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape.

Authors:  Liyang Lyu; Ye Feng; Xin Chen; Yuanjia Hu
Journal:  Nat Biotechnol       Date:  2020-12       Impact factor: 54.908

3.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Authors:  Syed Abbas Ali; Victoria Shi; Irina Maric; Michael Wang; David F Stroncek; Jeremy J Rose; Jennifer N Brudno; Maryalice Stetler-Stevenson; Steven A Feldman; Brenna G Hansen; Vicki S Fellowes; Frances T Hakim; Ronald E Gress; James N Kochenderfer
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

Review 4.  Harnessing innate immunity in cancer therapy.

Authors:  Olivier Demaria; Stéphanie Cornen; Marc Daëron; Yannis Morel; Ruslan Medzhitov; Eric Vivier
Journal:  Nature       Date:  2019-10-02       Impact factor: 49.962

5.  Emerging CAR T cell therapies: clinical landscape and patent technological routes.

Authors:  Virgínia Picanco-Castro; Cristiano Gonçalves Pereira; Kamilla Swiech; Kelen Cristina Ribeiro Malmegrim; Dimas Tadeu Covas; Geciane Silveira Porto
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

6.  Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.

Authors:  Jiangtao Ren; Xiaojun Liu; Chongyun Fang; Shuguang Jiang; Carl H June; Yangbing Zhao
Journal:  Clin Cancer Res       Date:  2016-11-04       Impact factor: 12.531

7.  Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

Authors:  Christoph Uherek; Torsten Tonn; Barbara Uherek; Sven Becker; Barbara Schnierle; Hans-Georg Klingemann; Winfried Wels
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

Review 8.  Chimeric antigen receptor therapy for cancer.

Authors:  David M Barrett; Nathan Singh; David L Porter; Stephan A Grupp; Carl H June
Journal:  Annu Rev Med       Date:  2013-11-20       Impact factor: 13.739

9.  Quantifying the publication preferences of leading research universities.

Authors:  Barbara S Lancho-Barrantes; Francisco J Cantu-Ortiz
Journal:  Scientometrics       Date:  2021-01-04       Impact factor: 3.238

Review 10.  Engineering CAR-T Cells for Next-Generation Cancer Therapy.

Authors:  Mihe Hong; Justin D Clubb; Yvonne Y Chen
Journal:  Cancer Cell       Date:  2020-07-30       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.